Pyrrolo-pyridine kinase modulators

Details Pyrrolo-pyridine kinase modulators Pyrrolo-pyridine kinase modulators

2011-03-15

2011-03-15

Chandrakumar, Nizal S (Department: 1625)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C514S218000

Reexamination Certificate

active

07906648

ABSTRACT:
The present invention provides novel pyrrolo-pyridine kinase modulators and methods of using the novel pyrrolo-pyridine kinase modulators to treat diseases mediated by kinase activity.

REFERENCES:
patent: 5019586 (1991-05-01), Oxford et al.
patent: 5051412 (1991-09-01), Macor
patent: 5338849 (1994-08-01), Festal et al.
patent: 5563150 (1996-10-01), Curtis et al.
patent: 5643734 (1997-07-01), Henderson
patent: 5681959 (1997-10-01), Bishop et al.
patent: 6335342 (2002-01-01), Longo et al.
patent: 6589950 (2003-07-01), Collingwood et al.
patent: 6699883 (2004-03-01), Doemling et al.
patent: 7186716 (2007-03-01), Wei et al.
patent: 2002/0119982 (2002-08-01), Wang et al.
patent: 2004/0019052 (2004-01-01), Garland et al.
patent: 2006/0035898 (2006-02-01), Arnold et al.
patent: 2007/0043068 (2007-02-01), Arnold et al.
patent: 10053122 (2001-05-01), None
patent: 1995915 (2001-08-01), None
patent: WO-96-32391 (1996-10-01), None
patent: WO-00-24694 (2000-05-01), None
patent: WO-00-43393 (2000-07-01), None
patent: WO-00-71537 (2000-11-01), None
patent: WO-02-24694 (2002-03-01), None
patent: WO-02-051837 (2002-07-01), None
patent: WO-02-051837 (2002-07-01), None
patent: WO-03-002563 (2003-01-01), None
patent: WO-03-024969 (2003-03-01), None
patent: WO-03-028724 (2003-04-01), None
patent: WO-03-045949 (2003-06-01), None
patent: WO-03-045949 (2003-06-01), None
patent: WO-03-068221 (2003-08-01), None
patent: WO-03-068773 (2003-08-01), None
patent: WO-03-82868 (2003-10-01), None
patent: WO-03-082869 (2003-10-01), None
patent: WO-03-087816 (2003-10-01), None
patent: WO-2004-014368 (2004-02-01), None
patent: WO-2004-024895 (2004-03-01), None
patent: WO-2004-032874 (2004-04-01), None
patent: WO-2004-078756 (2004-09-01), None
patent: WO-2004-078756 (2004-09-01), None
patent: WO-2004-078757 (2004-09-01), None
patent: WO-2005-078757 (2004-09-01), None
patent: WO-2004-101565 (2004-11-01), None
patent: WO-2004-101565 (2004-11-01), None
patent: WO-2005-028475 (2005-03-01), None
patent: WO-2005-062795 (2005-07-01), None
patent: WO-2005-062795 (2005-07-01), None
patent: WO-2005-085244 (2005-09-01), None
patent: WO-2005-095400 (2005-10-01), None
patent: WO-2006-015123 (2006-02-01), None
patent: WO-2006-124863 (2006-11-01), None
patent: WO-2007-106236 (2007-09-01), None
Witherington et al., “5-Aryl-pyrazolo[3,4-b]pyridines: Potent Inhibitors of Glycogen Synthase Kinase-3 (GSK-3),” Bioorg. Med. Chem. Ltrs. 13:1577-1580 (2003).
Bartram et al., “Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia,” Nature 306:277-280 (1983).
Buchdunger, E. et al., “Abl Protein-Tyrosene Kinase Inhibitor STI571 Inhibits in Vitro Signal Transduction Mediated by c-Kit and Platelet-Derived Growth Factor Receptors,” J. Pharm. Exp. Ther. 295 (1):139-145 (2000).
Chan et al., “A novel abl protein expressed in Philadelphia chromosome positive acute lymphoblastic leukaemia.,” Nature 325:635-637 (1987).
Druker et al., “Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells,” Nat. Med. 2:561-566 (1996).
Druker et al., “Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia,” N. Engl. J. Med. 344(14):1031 (2001).
Druker et al., “Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the philadelphia chromosome,” N. Engl. J. Med. 344(14):1038 (2001).
Gorre et al., “Clinical resistance to STI-571 cancer therapy caused by BCRABL gene mutation or amplification,” Science 293:876-880 (2001).
Groffen et al., “Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22,” Cell 36: 93-99 (1984).
Hughes et al., “Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia,” N. Engl. J. Med 349: 1423-1432 (2003).
Kantarjian, H. and Talpaz, M., “Definition of the Accelerated Phase of Chronic Myelogenous Leukemia,” Letter to the Editor, J. Clin. Onc. 6(1):180-181 (1988).
Lugo et al., “Tyrosine kinase activity and transformation potency of bcr-abl oncogene products,” Science 247: 1079-1082 (1990).
Ottman, O.G. et al., “A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias,” Blood 100:1965-1971 (2000).
Sawyer, C.L. et al., “Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results in phase II study,” Blood 99:3530-3539 (2002).
Simonsson, B. et al., “Beneficial Effects of Cytogenetic and Molecular Response on Long-Term Outcome in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib (M): Update from the IRIS Study,” Blood 106(11):52a (2005) (Abstract.
Milella et al., “The Mitogen-Activated Protein Kinase Signaling Module As A Therapeutic Target in Hematologic Malignancies,” Reviews in Clinical and Experimental Hematology 7(2):160-190 (2003).
PCT/US05/26792 Search Report dated Nov. 28, 2005.
PCT/US07/002123 Search Report dated Dec. 21, 2007.
Adamczyk et al., “Synthesis of 3,7-dihydroimidazol[1,2a]pyrazine-3-ones and their chemiluminescent properties,” Tetrahedron 59:8129-8143 (2003).
Altschul et al., “Gapped BLAST and PSI-BLAST: a new generation of protein database search programs,” Nucl. Acids Res. 24:3389-3402 (1997).
Arduengo et al., “Adducts of Carbenes with Group II and XII Metallocenes,” Organometallics 17:3375-3382 (1998).
Arduengo et al., “Low-Coordinate Carbene Complexes of Nickel(0)and Platinum(0)†,” J. Am. Chem. Soc. 116:4391-4394 (1994).
Bach et al., “Synthesis of 2′-Substituted 4-Bromo-2,4′-bithiazoles by Regioselective Cross-Coupling Reactions,” J. Org. Chem. 67:5789-5795 (2002).
Berge et al., “Pharmaceutical Salts,” J. Pharma. Sci. 66:1-19 (1977).
Blaney, J.M. and Dixon, J.S., “A good ligand is hard to find: Automated docking methods,” Perspectivesin Drug Discovery and Design 1:301-319 (1993).
Bolm et al., “Iron-Catalyzed Reactions in Organic Synthesis,” Chem. Rev. 104:6217-6254 (2004).
Boudier et al., “New Applications of Polyfunctional Organometallic Compounds in Organic Synthesis,” Angew. Chem. Int. Ed. 39: 4414-4435 (2000).
Brooks et al., “CHARMM: A program for macromolecular energy, minimization, and dynamics calculations,” J. Comp. Chem. 4:187-217 (1983).
Charifson et al., “Consensus Scoring: A Method for Obtaining Improved Hit Rates from Docking Databases of Three-Dimensional Structures into Proteins,” J. Med. Chem. 42:5100-5109 (1999).
Crabtree, S. et al., “Facile and Gentle Method for Quantitative Lysis ofEscherichia coliandSalmonella typhimurium,” J. Bacteriol. 158(1):354-356 (1984).
Deininger, M. et al., “The development of imatinib as a therapeutic agent for chronic myeloid leukemia,” Blood 105(7):2640-2653 (2005).
Feldman et al. “Novel Small Molecule Inhibitors of 3-Phosphoinositide-Dependent Kinase-1 (PDK1),” JBC Papers in Press, Published Mar. 16, 2005 Manuscript M501367200.
Furstner et al., “Iron-Catalyzed Cross-Coupling Reactions,” J. A. Chem. Soc. 124:13856-13863 (2002).
Goodsell & Olsen, “Automated Docking of Substrates to Proteins by Simulated Annealing,” Proteins: Structure, Function and Genetics 8:195-202 (1990).
Harrington et al., “VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo,” Nature Medicine Advance Online Publication Feb. 22, 2004, pp. 1-6.
Hartwig, Acc. “Carbon-Heteroatom Bond-Forming Reductive Eliminations of Am

Affiliated with

Also associated with

Rating

Pyrrolo-pyridine kinase modulators does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pyrrolo-pyridine kinase modulators, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrrolo-pyridine kinase modulators will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2630214